2Yin OQ,Tomlinson B,Chow MS.CYP2C9,but not CYP2C19,polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects.Clin Pharmacol Ther,2005,78:370-377.
3Holstein A,Plaschke A,Ptak M,et al.Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents.Br J Clin Pharmacol,2005,60:103-106.
4Becker ML,Visser LE,Trienekens PH,et al.Cytochrome P4502C9 * 2 and * 3 polymorphisms and the dose and effect of sulfonylurea in type Ⅱ diabetes mellitus.Clin Pharmocol Ther,2008,83:288-292.
5Kirchheiner J,Meineke I,Muller G,et al.Influence of CYP2C9and CYP2D6 polymorphisms on the pharnacokinetics of nateglinide in genotyped healthy volunteers.J Clin Pharmacokinet,2004,43:267-278.
6Niemi M,Schaeffeler E,Lang T,et al.High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C,SLCO1B1).Pharmacogenetics,2004,14:429-440.
7Kameyama Y,Yamashita K,Kobayashi K,et al.Functional characterization ofSLCO1B1 (OATP-C) variants,SLCO1B1 *5,SLCO1B1 * 15 and SLCO1B1 * 15 + C1007G,by using transient expression systems of HeLa and HEK293 cells.Pharmacogenet Genomics,2005,15:513-522.
8Zhang W,He YJ,Han CT,et al.Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide.Br J Clin Pharmacol,2006,62:567-572.
9Niemi M,Backman.JT,Kajosaari LI,et al.Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.Clin Pharmacol Ther,2005,77:468-478.
10Choi MK,Song IS.Organic cation transporters and their pharmacokinetic and pharmacodynamic consequence.Drug Metal Pharmacokinet,2008,23:243-253.
3Hart LM,de Knijff P,Dekker JM,et al.Variants in the sulphonylurea receptor gene:association of the exon 16-3t variant with type Ⅱ diabetes mellitus in Dutch Caucasians.Diabetologia,1999,42:617-620.
4Monnier L,Lapinski H,Colette C.Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients.Variations with increasing levels of HbA1c.Diabetes Care,2003,26:881-885.
5Kim H,Yun M,Kwon KI.Pharmacokinetic and pharmacodynamic characterization of gliclazide in healthy volunteers.Arch Pharm Res,2003,26:564-568.
